JP2020515598A - インジルビン及びその誘導体を含有する新規の医薬製剤並びにその製造方法及び使用方法 - Google Patents

インジルビン及びその誘導体を含有する新規の医薬製剤並びにその製造方法及び使用方法 Download PDF

Info

Publication number
JP2020515598A
JP2020515598A JP2019553439A JP2019553439A JP2020515598A JP 2020515598 A JP2020515598 A JP 2020515598A JP 2019553439 A JP2019553439 A JP 2019553439A JP 2019553439 A JP2019553439 A JP 2019553439A JP 2020515598 A JP2020515598 A JP 2020515598A
Authority
JP
Japan
Prior art keywords
indirubin
solvent
dihydro
indole
derivative
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019553439A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020515598A5 (enExample
Inventor
ウー，ビン
バウチャー，ポール
Original Assignee
フォスフォレックス，インコーポレーテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by フォスフォレックス，インコーポレーテッド filed Critical フォスフォレックス，インコーポレーテッド
Publication of JP2020515598A publication Critical patent/JP2020515598A/ja
Publication of JP2020515598A5 publication Critical patent/JP2020515598A5/ja
Priority to JP2023000437A priority Critical patent/JP2023040147A/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5192—Processes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2019553439A 2017-03-29 2018-03-29 インジルビン及びその誘導体を含有する新規の医薬製剤並びにその製造方法及び使用方法 Pending JP2020515598A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023000437A JP2023040147A (ja) 2017-03-29 2023-01-05 インジルビン及びその誘導体を含有する新規の医薬製剤並びにその製造方法及び使用方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762478317P 2017-03-29 2017-03-29
US62/478,317 2017-03-29
PCT/US2018/025075 WO2018183631A1 (en) 2017-03-29 2018-03-29 Novel pharmaceutical formulations containing indirubin and derivatives thereof and methods of making and using the same

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023000437A Division JP2023040147A (ja) 2017-03-29 2023-01-05 インジルビン及びその誘導体を含有する新規の医薬製剤並びにその製造方法及び使用方法

Publications (2)

Publication Number Publication Date
JP2020515598A true JP2020515598A (ja) 2020-05-28
JP2020515598A5 JP2020515598A5 (enExample) 2021-05-06

Family

ID=63676834

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019553439A Pending JP2020515598A (ja) 2017-03-29 2018-03-29 インジルビン及びその誘導体を含有する新規の医薬製剤並びにその製造方法及び使用方法
JP2023000437A Withdrawn JP2023040147A (ja) 2017-03-29 2023-01-05 インジルビン及びその誘導体を含有する新規の医薬製剤並びにその製造方法及び使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023000437A Withdrawn JP2023040147A (ja) 2017-03-29 2023-01-05 インジルビン及びその誘導体を含有する新規の医薬製剤並びにその製造方法及び使用方法

Country Status (7)

Country Link
US (3) US20200016087A1 (enExample)
EP (1) EP3600259A4 (enExample)
JP (2) JP2020515598A (enExample)
CN (2) CN115969814A (enExample)
AU (1) AU2018244442A1 (enExample)
CA (1) CA3058407A1 (enExample)
WO (1) WO2018183631A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022116295A (ja) * 2019-04-17 2022-08-09 アゾーラ セラピューティクス，インコーポレイテッド 炎症性皮膚疾患を処置するための局所組成物及び方法

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101855423B1 (ko) * 2017-04-18 2018-05-09 주식회사 씨케이바이오텍 인디루빈 유도체를 유효성분으로 포함하는 약학 조성물
CN114521142B (zh) 2019-11-04 2024-07-02 Ck雷容股份有限公司 用于抑制和/或治疗神经退行性疾病和/或其临床病症的组合物和方法
CN115252610B (zh) * 2020-02-26 2024-03-26 上海科技大学 质子泵抑制剂在抗冠状病毒中的应用
US20240226063A1 (en) * 2021-04-29 2024-07-11 Jawaharlal Nehru Centre For Advanced Scientific Research Soluble analogues of 6bio thereof and implementation thereof
MX2024004264A (es) 2021-10-08 2024-07-10 Azora Therapeutics Inc Derivados de agonistas de los receptores de aril hidrocarburos.
CN114668744A (zh) * 2022-03-23 2022-06-28 成都大学 一种靛玉红固体脂质纳米粒及其制备方法

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012012616A1 (en) * 2010-07-21 2012-01-26 Patty-Fu Giles Photoactive vitamin nanoparticles for the treatment of chronic wounds
JP2015508787A (ja) * 2012-02-29 2015-03-23 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ 活性化合物を取り込んだナノ粒子の製造プロセス
JP2015520241A (ja) * 2012-06-21 2015-07-16 フォスフォレックス，インコーポレーテッド インジルビンのナノ微粒子、その誘導体およびそれらを作製しかつ利用する方法
CN103550206B (zh) * 2013-10-23 2015-11-25 重庆市中药研究院 一种白藜芦醇靛玉红组合药物、缓释微囊剂及其应用
WO2016197262A1 (en) * 2015-06-12 2016-12-15 Bayer Pharma Aktiengesellschaft Process for the preparation of porous microparticles
WO2017031144A1 (en) * 2015-08-17 2017-02-23 Phosphorex, Inc. Extremely small nanoparticles of degradable polymers

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1686988A1 (en) * 2003-10-28 2006-08-09 The Rockefeller University Indirubin-type compounds, compositions, and methods for their use
US9193954B2 (en) * 2011-03-31 2015-11-24 University Of Rochester Methods and compositions for mesenchymal stem cell proliferation
WO2013124867A1 (en) * 2012-02-21 2013-08-29 Amrita Vishwa Vidyapeetham University Polymer - polymer or polymer - protein core - shell nano medicine loaded with multiple drug molecules
US9707186B2 (en) * 2012-02-21 2017-07-18 Amrita Vishwa Vidyapeetham Core-shell particle formulation for delivering multiple therapeutic agents
WO2014152451A2 (en) * 2013-03-14 2014-09-25 University Of Rochester Compositions and methods for controlled localized delivery of bone forming therapeutic agents
EP2878312A1 (en) * 2013-12-02 2015-06-03 Albert-Ludwigs-Universität Freiburg Reversible PEGylation of nanocarriers
WO2015095659A2 (en) * 2013-12-20 2015-06-25 Phosphorex, Inc. Indirubin solid dispersion composition

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012012616A1 (en) * 2010-07-21 2012-01-26 Patty-Fu Giles Photoactive vitamin nanoparticles for the treatment of chronic wounds
JP2015508787A (ja) * 2012-02-29 2015-03-23 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ 活性化合物を取り込んだナノ粒子の製造プロセス
JP2015520241A (ja) * 2012-06-21 2015-07-16 フォスフォレックス，インコーポレーテッド インジルビンのナノ微粒子、その誘導体およびそれらを作製しかつ利用する方法
CN103550206B (zh) * 2013-10-23 2015-11-25 重庆市中药研究院 一种白藜芦醇靛玉红组合药物、缓释微囊剂及其应用
WO2016197262A1 (en) * 2015-06-12 2016-12-15 Bayer Pharma Aktiengesellschaft Process for the preparation of porous microparticles
WO2017031144A1 (en) * 2015-08-17 2017-02-23 Phosphorex, Inc. Extremely small nanoparticles of degradable polymers

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
INTERNATIONAL JOURNAL OF NANOMEDICINE, vol. 10, JPN6021050181, 2015, pages 4691 - 4703, ISSN: 0004867424 *
POLYMER BULLETIN, vol. 53, JPN6021050182, 2005, pages 147 - 154, ISSN: 0004867423 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022116295A (ja) * 2019-04-17 2022-08-09 アゾーラ セラピューティクス，インコーポレイテッド 炎症性皮膚疾患を処置するための局所組成物及び方法

Also Published As

Publication number Publication date
CN110709066A (zh) 2020-01-17
CN115969814A (zh) 2023-04-18
WO2018183631A8 (en) 2019-08-15
US20230100193A1 (en) 2023-03-30
US20200383931A1 (en) 2020-12-10
WO2018183631A1 (en) 2018-10-04
CA3058407A1 (en) 2018-10-04
JP2023040147A (ja) 2023-03-22
EP3600259A1 (en) 2020-02-05
AU2018244442A1 (en) 2019-10-24
US20200016087A1 (en) 2020-01-16
EP3600259A4 (en) 2020-11-25

Similar Documents

Publication Publication Date Title
JP2023040147A (ja) インジルビン及びその誘導体を含有する新規の医薬製剤並びにその製造方法及び使用方法
JP4057849B2 (ja) 薬剤と濃度を高めるポリマーとを含む医薬組成物
KR101722794B1 (ko) 약물 전달을 위한 조성물 및 방법
CN106061261B (zh) 治疗化合物的结晶形式及其用途
KR102168263B1 (ko) 주사 제제
KR101267782B1 (ko) 이마티닙 메실레이트의 안정화된 무정형 형태
US20130209521A1 (en) Nanostructured aprepitant compositions, process for the preparation thereof and pharmaceutical compositions containing them
CN104936589A (zh) 具有改善的生物利用度的药物组合物
WO2016155655A1 (zh) Parp抑制剂固体药物剂型及其应用
JP2010512397A (ja) アンサマイシン製剤およびその使用法
ES3025474T3 (en) Compositions of substituted pyrazolopyrimidines and uses thereof
CN101426477A (zh) 纳米颗粒卡维地洛制剂
JP2018504443A (ja) 酢酸アビラテロンの複合体、その製造のための方法、およびそれらを含有する医薬組成物
CN101677568A (zh) 齐拉西酮制剂
US20210315831A1 (en) Preparation of nanosuspension comprising nanocrystals of active pharmaceutical ingredients with little or no stabilizing agents
JP5288791B2 (ja) 難水溶性物質含有微細化組成物
Panda et al. RETRACTED: Self-assembled phenylalanine-α, β-dehydrophenylalanine nanotubes for sustained intravitreal delivery of a multi-targeted tyrosine kinase inhibitor
CN104274401A (zh) 一种基于hcpt-peg的喜树碱类药物的高载药纳米混悬剂及其制备方法
CN109982704B (zh) 药物制剂
CN110384803B (zh) 一种大环主体分子作为药物增溶剂的应用
JP2009504615A (ja) ７−（ｔ−ブトキシ）イミノメチルカンプトテシンのための製剤
MX2007016081A (es) Formulacion farmaceutica del inhibidor de tubulina, indibulina, para administracion oral con propiedades farmacocineticas mejoradas, y proceso para la fabricacion de la misma.
CN118766866A (zh) 改善治疗剂的溶解度和生物利用度的方法
WO2024211881A1 (en) Rimegepant suspension
Martin Preparation of etoposide nanocrystals suspension by co-precipitation for enhanced targeting and sustained release in cancer therapy

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210325

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210325

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20211213

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220104

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220401

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20220906